Table 1.

Percentage of patients with events of uveitis on Randomized Controlled Trials

UveitisRandomized Controlled Trials
% patients with events under therapy% patients with events under placebo
Infliximab2,98,6
Etanercept1,13,5
AdalimumabNo resultsNo results
GolimumabNo resultsNo results
Certolizumab pegol0,92,8